[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-pancreatic-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-pancreatic-cancers":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,69,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100618016","a-prospective-observational-study-of-first-line-systemic-therapy-combined-with-celiac-plexus-blockade-for-advanced-biliopancreatic-cancer-with-pain-100618016",false,"NCT07326137","A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade in Patients With Advanced Biliopancreatic Malignancies and Cancer-Related Pain","Inclusion Criteria:\n\n* Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer).\n* Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN).\n* Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1\u002FPD-L1 inhibitor monotherapy or in combination with chemotherapy\u002Ftargeted therapy).\n* ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months.\n\nExclusion Criteria:\n\n* Previous history of celiac plexus neurolysis or ablation.\n* Coagulation disorders (INR \\> 1.5, platelet count \\\u003C 50 × 10⁹\u002FL).\n* Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin, NYHA Class III-IV heart failure).\n* Contraindications to celiac plexus block (e.g., local infection, anatomical variation).\n* Any other condition that, in the investigator's judgment, would preclude safe participation in the study.","ALL",{"count":18,"type":19},103,"ESTIMATED","OBSERVATIONAL","This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs.\n\nPatients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes.\n\nThe goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.",[23,24,25],"Advanced Biliary Tract Cancer(BTC)","Advanced Pancreatic Cancers","Cancer-related Pain","RECRUITING","2026-02-10",{"date":29,"type":30},"2026-02-11","ACTUAL",{"date":32,"type":30},"2025-12-26",{"date":34,"type":19},"2028-12-26",{"name":36,"class":37},"Tongji Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":38},"100446804","early-phase-1-a-study-of-gc101-til-in-advanced-hepatobiliary-pancreatic-cancers-10hospital-100446804","NCT05098197","A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Hepatobiliary-Pancreatic Cancers","Inclusion Criteria:\n\n1. Age: 18 years to 75 years;\n2. Histologically diagnosed as primary\u002Frelapsed\u002Fmetastasized hepatobiliary cancer or pancreatic cancers;\n3. Expected life-span more than 3 months;\n4. Karnofsky≥60% or ECOG score 0-2;\n5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;\n7. At least 1 evaluable tumor lesion;\n8. Hematology and Chemistry（within 7 days prior to enrollment）:\n\n   * Absolute count of white blood cells≥2.5×10\\^9\u002FL;\n   * Absolute count of neutropils≥1.5×10\\^9\u002FL;\n   * Absolute count of lymphocytes ≥0.7×109\u002FL；\n   * Platelet count≥100×10\\^9；\n   * hemoglobin≥90 g\u002FL;\n   * Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);\n   * International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);\n   * Serum creatinine ≤1.5mg\u002FdL(or ≤132.6μmol\u002FL), or clearance rate≥50mL\u002Fmin;\n   * Serum ALT\u002FAST ≤3×ULN(subjects with liver metastasis ≤3×ULN);\n   * Totol bilirubin≤1.5×ULN;\n9. no absolute or relative contraindications to operation or biopsy;\n10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion；\n11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;\n12. Be able to understand and sign the informed consent document;\n13. Be able to stick to follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;\n2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;\n3. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.\n4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;\n5. Severe physical or mental diseases;\n6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);\n7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;\n8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;\n9. Having received immunotherapy and developed irAE level greater than Level 3;\n10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);\n11. Females in pregnancy or lactation;\n12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;\n13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.","18 Years","75 Years",{"count":49,"type":19},50,"INTERVENTIONAL",[52],"EARLY_PHASE1","This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",[55,56,57,58,24],"Advanced Liver Cancers","Tumor Infiltrating Lymphocyte","Treatment Side Effects","Effects of Immunotherapy","2025-12-04",{"date":61,"type":30},"2025-12-11",{"date":63,"type":30},"2021-09-26",{"date":65,"type":19},"2026-09-25",{"name":67,"class":68},"Shanghai Juncell Therapeutics","INDUSTRY",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100575296","phase-2-ibi343-combined-with-chemotherapy-in-advanced-pancreatic-cancer-100575296","NCT06770439","IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Signed written informed consent, willing and able to comply with the protocol specified visits and related procedures.\n* Histopathologically confirmed unresectable locally advanced, recurrent, or metastatic pancreatic adenocarcinoma.\n* Subjects must not be eligible for radical treatment such as radical radiotherapy and \u002F or surgery; time to disease recurrence \u002F metastasis\\> 6 months for subjects with previous (new) adjuvant \u002F adjuvant \u002F radiotherapy) chemotherapy \u002F radical chemoradiotherapy. In part 1: locally advanced or recurrent \u002F metastatic stage with or without systemic therapy (including chemotherapy, targeted therapy, tumor immunotherapy, etc.). In part 2: The locally advanced or recurrent \u002F metastasis phase has not received any systemic therapy (including chemotherapy, targeted therapy, tumor immunotherapy, etc.).\n* At least 1 measurable lesion (no previous radiotherapy) for solid tumors RECIST v1.1.(At baseline, computed tomography or magnetic resonance imaging showed the long diameter of 10 mm (except for lymph nodes, the short axis of the lymph node must be 15 mm), the diameter of the target lesion is 2 times the imaging layer thickness and the lesion is suitable for repeated accurate measurement. If a lesion located in the previously irradiated area clearly demonstrates a progression meeting the RECIST V1.1 criteria, the lesion acts as a measurable lesion).\n* Age was 18 years, and gender was unlimited.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0 or 1.\n* The expected survival period was estimated at 12 weeks.\n* Sufficient bone marrow and organ function.\n* Female subjects of childbearing age or male partners of childbearing age should take effective contraception throughout the treatment period and within 6 months after the treatment period.\n* Pathological tissue testing was confirmed as CLDN18.2 positive.\n\nExclusion Criteria:\n\n* Is participating in another interventional clinical study, except for an observational (non-interventional) clinical study or is in the survival follow-up phase of the interventional study.\n* Treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) before the first dose of the study drug.\n* The last anti-tumor therapy within 4 weeks before the first dose of the study drug or within 5 half-lives of the anti-tumor treatment (whichever is shorter) (2 weeks for washout with no exact half-life).\n* Received therapeutic or palliative radiotherapy within 2 weeks prior to the first administration of the study drug.\n* Receiving biliary stenting or PTCD within 7 days prior to the first use of study drug.\n* Other anti-tumor treatment is planned during the study medication \\[allows palliative radiotherapy for the purpose of relieving symptoms (e. g. pain) and does not affect efficacy evaluation\\].\n* Any live vaccine is administered within 4 weeks before the first dose of the study drug or during the duration of the study.\n* A major surgical procedure (craniotomy, otomy, or tomy or otherwise defined by the investigator, excluding needle biopsy within 4 weeks before the first dose of study drug) or the presence of an unhealed wound, ulcer, or fracture; or a requirement that major surgery is planned during the study. For the purpose of palliative care, the local surgical treatment of isolated lesions is acceptable.\n\nAny live vaccine within 4 weeks before the first dose of the study drug or during the duration of the study.\n\n* A major surgical procedure (craniotomy, otomy, or tomy or otherwise defined by the investigator, excluding needle biopsy within 4 weeks before the first dose of study drug) or the presence of an unhealed wound, ulcer, or fracture; or a planned major surgery required during the study. For the purpose of palliative care, the local surgical treatment of isolated lesions is acceptable.\n* Failure to recover to grade 0 or 1 prior to the first dose of study drug of NCI CTCAE v5.0 (excluding alopecia, fatigue, pigmentation, and other conditions with no safety risk as judged by the investigator).\n* A history of gastrointestinal perforation and \u002F or fistula within 6 months prior to the first dose of study drug was not resolved by surgery. presence of pyloric obstruction and \u002F or persistent recurrent vomiting (3 times within 24 hours).\n* After gastrointestinal or tracheal lumen stenting.\n* Symptomatic CNS metastasis. For subjects with asymptomatic brain metastases (i. e., no glucocorticoid treatment, 1.5 cm treatment) or stable brain metastases after treatment, all the following criteria were required to participate in this study: no meson, pons, cerebellum, meninges, medullary or spinal cord metastasis; remained clinically stable for at least 4 weeks, confirmed clinical evidence of no new or expanded brain metastases, and stopped corticosteroid and anticonvulsant therapy for at least 2 weeks before the first dose of study drug. Note: The CNS is not used as a target lesion.\n* Bone metastases at risk of paraplegia.\n* Interstitial lung disease requiring steroid hormone therapy, or a history of - interstitial lung disease, non-infectious pneumonia, severely impaired or uncontrolled lung function, such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, or is suspected during screening.\n* There are diseases that fail to control History of the other primary malignancies.\n* A known medical history of immunodeficiency.\n* History of allogeneic organ transplantation and allogeneic HSCT.\n* Previous treatment with antibody drug conjugates based on topoisomerase inhibitors.\n* For medicated subjects, there was a previous history of allergy to the appropriate drug or preparation.\n* For subjects receiving medication, there are contraindications to the drug.\n* There was a history of prior drug-related non-morbidity.\n* Female subjects in pregnancy or lactation.\n* Other investigators are not eligible for participation in this study.",{"count":77,"type":19},64,[79],"PHASE2","This study is a phase II study to evaluate the safety, tolerability and efficacy of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer, including Part1 (safe lead-in phase) and Part2 (extension phase). In part1, patients with CLDN18.2-positive advanced pancreatic adenocarcinoma who had or had not previously received systemic therapy were treated with chemotherapy in IBI343 with AG regimen (albumin paclitaxel with gemcitabine). In part2, 40 patients with CLDN18.2-positive advanced PDAC will be enrolled, 1:1 randomized to Arm A and Arm B, respectively. In Arm A, patients will receive IBI343 TBD + gemcitabine TBD + albumin-bound paclitaxel TBD; and in Arm B, patients will receive gemcitabine 1000mg \u002F m2 d1, d8 Q3W + albumin-bound paclitaxel 125mg \u002F m2d1, d8 Q3W treatment.",[24],"2025-09-18",{"date":84,"type":30},"2025-09-23",{"date":86,"type":30},"2025-04-18",{"date":88,"type":19},"2028-01",{"name":90,"class":37},"Zhejiang University",2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":50,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":38},"100574521","phase-1-a-clinical-study-of-cht102-in-msln-positive-advanced-pancreatic-cancer-100574521","NCT06760364","A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer","A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer","CHAMPION","Inclusion Criteria:\n\n1. Ability to understand and sign a written informed consent documen；\n2. At the date of signing ICF, 18 \\~70 years old, male or female；\n3. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；\n4. Positive mesothelin expression;\n5. At least one measurable lesion at baseline per RECIST version 1.1；\n6. The expected survival time is more than 12 weeks;\n7. ECOG 0-1 points;\n8. Adequate organ functions.","70 Years",{"count":102,"type":19},21,[104],"PHASE1","Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer",[24],[108,109,110,111],"Allogeneic CAR-T","Safety","Efficacy","PK","2025-04-07",{"date":114,"type":30},"2025-04-10",{"date":116,"type":30},"2024-12-25",{"date":118,"type":19},"2039-12-24",{"name":120,"class":37},"Tianjin Medical University Cancer Institute and Hospital"]